

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

Information for the public

Published: 3 June 2026

www.nice.org.uk

Durvalumab (Imfinzi) is available on the NHS. It is a possible treatment for gastric (stomach) or gastro-oesophageal junction (where the food pipe meets the stomach) adenocarcinoma that can be removed surgically in adults. It can be used:

- with chemotherapy both before (neoadjuvant) and after surgery (adjuvant), then
- by itself as adjuvant treatment.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpages on oesophageal cancer](#) or [stomach cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Stomach Cancer UK](#), 0300 030 0689
- [Guts UK](#), 0300 102 4887
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9528-8